Amarin Corp Plcuk (AMRN) Change in Acquisitions & Divestments (2020 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Change in Acquisitions & Divestments of $45.9 million for Q2 2026, down 8.79% year-over-year from $50.3 million in Q2 2025, and up 7.95% quarter-over-quarter from $42.5 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Change in Acquisitions & Divestments (2020 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Change in Acquisitions & Divestments for 7 consecutive years, with $45.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Acquisitions & Divestments fell 8.79% year-over-year to $45.9 million; the TTM figure through Jun 2026 stood at $192.4 million (down 6.2% YoY), while the FY2025 annual figure was $209.3 million, down 10.09% from the prior year.
- Change in Acquisitions & Divestments advanced to $45.9 million in Q2 2026 per AMRN's latest filing, from $42.5 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $113.2 million in Q1 2022 and bottomed at $16.9 million in Q4 2022.
- Historically, Change in Acquisitions & Divestments has averaged $54.3 million across 5 years, with a median of $53.5 million in 2022.
- Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments slumped 79.42% — and 2024, when it soared 88.38%.
- Amarin Corp Plc\Uk's Change in Acquisitions & Divestments stood at $16.9 million in 2022, then jumped by 72.19% to $29.1 million in 2023, then surged by 61.45% to $47.0 million in 2024, then advanced by 0.0% to $47.0 million in 2025, then slipped by 2.39% to $45.9 million in 2026.
- Business Quant data shows AMRN's Change in Acquisitions & Divestments at $45.9 million in Q2 2026, $42.5 million in Q1 2026, and $47.0 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.88 Mn |
| Jun 30, 2026 | 45.88 Mn |
| Mar 31, 2026 | 42.50 Mn |
| Mar 31, 2026 | 42.50 Mn |
| Dec 31, 2025 | 47.00 Mn |
| Dec 31, 2025 | 47.00 Mn |
| Sep 30, 2025 | 57.00 Mn |
| Sep 30, 2025 | 57.00 Mn |
| Jun 30, 2025 | 50.30 Mn |
| Jun 30, 2025 | 50.30 Mn |
| Mar 31, 2025 | 55.00 Mn |
| Mar 31, 2025 | 55.00 Mn |
| Dec 31, 2024 | 47.00 Mn |
| Dec 31, 2024 | 47.00 Mn |
| Sep 30, 2024 | 52.80 Mn |
| Sep 30, 2024 | 52.80 Mn |
| Jun 30, 2024 | 71.00 Mn |
| Jun 30, 2024 | 71.00 Mn |
| Mar 31, 2024 | 62.00 Mn |
| Mar 31, 2024 | 62.00 Mn |